FDA 483 - Kai Huang - May 16, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Kai Huang, a Clinical Investigator in Wuxi, China, was cited for two significant observations during an FDA inspection. The inspection revealed failures in performing a clinical study according to good clinical practices, including unauthorized extended subject housing during COVID-19 lockdowns and inadequate documentation. Additionally, the firm failed to meet general informed consent requirements, notably involving a subject's partner being pressured to terminate a pregnancy.
ID · f11045d7-21b0-4e55-9c7a-15b82057df9f